While others divest, Sandoz expands: "Antibiotics are the backbone of modern medicine"
Unlike many large pharmaceutical companies, Sandoz is still investing in antibiotics, most recently through the acquisition of a GSK portfolio and an expansion in European production. This business area will remain central to the company, says Carol Lynch.
by elizabeth mønsted johansen, translated by catherine brett
The antibiotics business at Sandoz has been on something of a rollercoaster ride over the past two years. After a spike in demand at the start of the pandemic, sales plummeted due to cancelled operations, and the company has only just started to see normalization on the market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
